polyinosinic-polycytidylic acid/inactivated rabies virus vaccine YS-ON-001

A cancer vaccine composed of inactivated rabies vaccine (RV-V) and polyinosinic-polycytidylic acid (poly IC; poly I-C), an immunostimulant and Toll-like receptor 3 (TLR3) agonist, with potential immunostimulating and antineoplastic activities. Upon administration of the poly IC/inactivated RV-V YS-ON-001, the RV-V stimulates the immune system in various ways, such as promoting the activation and proliferation of T helper type 1 (Th1) cells, dendritic cells (DCs), B cells and natural killer cells (NKs), promoting macrophage M1 polarization, downregulating regulatory T cells (Tregs), and inducing the production of anti-tumor cytokines. This re-activates immune responses in the suppressed tumor microenvironment (TME), leading to an induction of cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells, which cause tumor cell apoptosis and a reduction of tumor cell proliferation. Poly IC, a synthetic double-stranded RNA with one strand composed of a inosinic acid polymer and the other strand a cytidylic acid polymer, binds to TLR3 and stimulates the release of cytotoxic cytokines, such as interferon-gamma (IFNg). This may boost the immune response against the tumor cells.